Known immune efficacy markers can be roughly divided into two categories: the first is related to tumor neoantigen load, including molecular markers such as MSI or TMB elevation, while the second is related to the tumor T cell inflammatory microenvironment, including core gene markers for PD-L1 protein expression, tumor lymphocyte infiltration and CNV (23). The gene discussed is CD274; the disease is neoplasm.